Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)

Autores: Melero Bermejo, Ignacio; Castañón Álvarez, Eduardo; Mau-Sorensen, M.; Lassen, U. N.; Lolkema, M. P.; Robbrecht, D. G. ; Gomez-Roca, C. A.; Martin-Liberal, J.; Tabernero, J.; Ros, W.; Ahmed, S.; Isambert, N.; Lepoutre, H. P.; Boetsch, C.; Charo, J.; Evers, S.; Teichgraber, V. ; Schellens, J. H. M.